Vigil Neuroscience Inc
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States. The company's lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells… Read more
Vigil Neuroscience Inc (VIGL) - Net Assets
Latest net assets as of June 2025: $41.26 Million USD
Based on the latest financial reports, Vigil Neuroscience Inc (VIGL) has net assets worth $41.26 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($86.70 Million) and total liabilities ($45.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $41.26 Million |
| % of Total Assets | 47.59% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 0.07 |
Vigil Neuroscience Inc - Net Assets Trend (2020–2024)
This chart illustrates how Vigil Neuroscience Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vigil Neuroscience Inc (2020–2024)
The table below shows the annual net assets of Vigil Neuroscience Inc from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $71.64 Million | -38.38% |
| 2023-12-31 | $116.25 Million | -38.52% |
| 2022-12-31 | $189.08 Million | +372.28% |
| 2021-12-31 | $-69.44 Million | -145.53% |
| 2020-12-31 | $-28.28 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vigil Neuroscience Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27848200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | 0.01% |
| Other Comprehensive Income | $27.00K | 0.04% |
| Other Components | $378.63 Million | 528.56% |
| Total Equity | $71.64 Million | 100.00% |
Vigil Neuroscience Inc Competitors by Market Cap
The table below lists competitors of Vigil Neuroscience Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Exmar NV
PINK:EXMRF
|
$220.20 Million |
|
Nanjing Toua Hardware&Tools Co.Ltd.
SHE:301125
|
$220.21 Million |
|
Sodick Co., Ltd.
PINK:SDCKF
|
$220.22 Million |
|
CLOUDBERRY CL.EN. NK -25
F:52K
|
$220.24 Million |
|
Oxford Biomedica plc
PINK:OXBDF
|
$220.17 Million |
|
Probe Metals Inc
OTCQB:PROBF
|
$220.06 Million |
|
Fujian Raynen Tech Co Ltd
SHG:603933
|
$220.06 Million |
|
Cabaletta Bio Inc
NASDAQ:CABA
|
$220.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vigil Neuroscience Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 116,252,000 to 71,635,000, a change of -44,617,000 (-38.4%).
- Net loss of 84,256,000 reduced equity.
- New share issuances of 29,352,000 increased equity.
- Other comprehensive income increased equity by 32,000.
- Other factors increased equity by 10,255,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-84.26 Million | -117.62% |
| Share Issuances | $29.35 Million | +40.97% |
| Other Comprehensive Income | $32.00K | +0.04% |
| Other Changes | $10.26 Million | +14.32% |
| Total Change | $- | -38.38% |
Book Value vs Market Value Analysis
This analysis compares Vigil Neuroscience Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.57x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-1.00 | $8.05 | x |
| 2021-12-31 | $3.37 | $8.05 | x |
| 2022-12-31 | $5.97 | $8.05 | x |
| 2023-12-31 | $3.00 | $8.05 | x |
| 2024-12-31 | $1.76 | $8.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vigil Neuroscience Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -117.62%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.64x
- Recent ROE (-117.62%) is below the historical average (-54.26%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-25.72 Million |
| 2021 | -46.76% | 0.00% | 0.00x | 1.11x | $-52.50 Million |
| 2022 | -35.82% | 0.00% | 0.00x | 1.06x | $-86.63 Million |
| 2023 | -71.09% | 0.00% | 0.00x | 1.21x | $-94.26 Million |
| 2024 | -117.62% | 0.00% | 0.00x | 1.64x | $-91.42 Million |
Industry Comparison
This section compares Vigil Neuroscience Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vigil Neuroscience Inc (VIGL) | $41.26 Million | 0.00% | 1.10x | $220.17 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |